BIZARRE: 4 - What They Never Told You

Novo Nordisk Stock Slides After Outlook Disappoints. But Wegovy Sales Continue to Climb

U.S.-listed shares of Novo Nordisk fell more than 6% after the company raised its full-year 2026 outlook but signaled that sales and profit could still decline compared with the previous year.

International Business Times · Aug 4

A Next-Generation Obesity Drug Has Been Released By Eli Lilly in Early Access to Select Patients

Eli Lilly will offer early access to the investigational obesity drug retatrutide after positive Phase 3 trials showed significant weight-loss results.

Medical Daily · Aug 4

Drugmaker Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts

Pfizer has reported impressive second-quarter earnings, driven by the success of Eliquis and newly acquired pharmaceutical products. The company is planning $2.5 billion in cost-saving measures expected to be in place by 2029. With a focus on innovative treatments, Pfizer aims to reduce reliance on older, high-grossing medications and looks…

The Economic Times · Aug 4

Alcohol’s hidden calories: product labels could help fight obesity in South Africa

South Africa is grappling with an obesity crisis. Nearly half of adults are overweight or obese. Public discussion often focuses on ultra-processed foods and sugary drinks as reasons for weight gain. But there’s another source of calories that’s often overlooked: alcoholic drinks.

The Conversation · Jul 30

GLP-1 Drugs Did Not Lower Relapse Risk in Crohn's and Colitis Patients, a Large Claims Analysis Found

A claims study found GLP-1 drugs did not reduce IBD relapse in patients with obesity or diabetes, and did not raise safety events.

Medical Daily · Jul 29

GLP-1 Medicare Coverage: How to Get It for $50 (And the Catch)

A new CMS program finally brings Wegovy and Zepbound within reach for seniors. But a hidden rule about your deductible could cost you thousands.

Kiplinger · Jul 29

Denied Coverage For Wegovy Or Zepbound? Here Is What The Latest Value Assessment Says About Price And Access

Denied for Wegovy or Zepbound? A new value analysis explains why plans refuse coverage and what exceptions and appeals actually involve.

Medical Daily · Jul 27

ICER Finds Weight-Loss Drugs Cost-Effective, But Analysts Warn the Projected Savings Depend on Patients Staying On Them

ICER finds GLP-1s cost-effective for obesity, but analysts warn projected savings assume patients stay on treatment. What it means for coverage.

Medical Daily · Jul 27

Millions of people are losing weight using GLP-1s. How do the drugs affect their love lives?

Prescribing doctors often warn of the medications’ potential side-effects – but unexpected impacts on romantic relationships are less understood

The Guardian - AU · Jul 25

Novo Nordisk pursues preliminary injunction to block Eli Lilly weight-loss drug ads

Novo Nordisk is seeking a court injunction to stop Eli Lilly's drug advertisements. The Danish company claims Lilly's ads mislead consumers about treatment comparisons. Lilly denies wrongdoing and stands by its advertising claims. Both companies compete in the growing obesity and diabetes drug market. Novo Nordisk argues Lilly uses outdated…

The Economic Times · Jul 24